If a patient is currently receiving denosumab, this must be discontinued prior to enrollment. Substitution with biphosphonates are acceptable.
Subjects with known metastases that are currently involving the lumen of the gastrointestinal tract.
Currently receiving experimental treatment with non-approved drugs at the time of enrolment. Patients must undergo a 28-day washout between last dose and screening CPET.
Patients currently receiving and unable to stop high doses of supplemental vitamin E
Patients currently receiving active treatment for melanoma
Currently receiving exogenous estrogen replacement therapy (topical vaginal estrogen therapy is allowed)
Patients who are currently receiving belimumab (a monoclonal antibody for systemic lupus erythematosus) are not eligible
Are currently receiving other medications intended for the treatment of their malignancy.
Currently using or planning to use:
Currently receiving progestin therapy (local, topical, or systemic)
History of hypertriglyceridemia or hypercholesterolemia and currently on medication(s)
Subject currently receiving abiraterone and prednisone for CRPC.
Patients currently receiving cancer therapy.
Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective.
Currently receiving or likely to require systemic immunosuppressive therapy from Day -7 to Day 29.
Is currently receiving and able to discontinue erlotinib, gefinitib, or afatinib.
Patients who are currently receiving an anti-IGF-IR monoclonal antibody as part of their treatment regimen
As per self report, currently engaged in ongoing acupuncture
Currently receiving radiation or chemotherapy
Are currently receiving other medications or radiation intended for the treatment of their malignancy
Currently using aluminum-containing antacid products
Patient is currently receiving clinical benefit from the treatment with IMCgp100, as determined by the principal investigator from the parent study
Currently receiving or ever received immunosuppressive therapy for an autoimmune disorder or an organ transplant
Patients currently receiving chemotherapy/biologic/immunotherapy as these need to be held during FFSRT
PART 2 GROUP 1 EXCLUSION CRITERIA: Subjects who are currently receiving treatment with agents that are known to cause QTc prolongation in humans; agents causing a strong signal will be prohibited
PART 2 GROUP 1 EXCLUSION CRITERIA: Subjects who are currently receiving treatment with drugs or herbal medications that can impact drug metabolism
PART 2 GROUP 2A EXCLUSION CRITERIA: Subjects who are currently receiving treatment with agents that are known to cause QTc prolongation in humans; agents causing a strong signal will be prohibited
PART 2 GROUP 2A EXCLUSION CRITERIA: Subjects who are currently receiving treatment with drugs or herbal medications that can impact drug metabolism
PART 2 GROUP 3 EXCLUSION CRITERIA: Subjects who are currently receiving treatment with agents that are known to cause QTc prolongation in humans; agents causing a strong signal will be prohibited
PART 2 GROUP 3 EXCLUSION CRITERIA: Subjects who are currently receiving treatment with drugs or herbal medications that can impact drug metabolism
Currently using hormone replacement therapy (oral or patch) or/and phytoestrogen supplements (i.e. black cohosh)
Currently receiving active therapy for other neoplastic disorders
Patients currently receiving active therapy for other neoplastic disorders
Patients who are currently receiving treatment with cidofovir, leflunomide, or other antiviral therapy with no response, will be eligible for CTL infusion
Patients who are currently receiving and responding to a different course of anti-neoplastic therapy, within the limits of acceptable toxicity per standard clinical practice, may not be enrolled to this study
Subjects with a diagnosis of metastatic disease who are currently receiving treatment or who have not been deemed in remission
HER2 therapy naive or currently receiving non-lapatinib HER2 targeted therapy
Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternatives
Patient is currently receiving treatment with ceritinib within a Novartis-sponsored study which has fulfilled the requirements for the primary objective and, in the opinion of the Investigator, would benefit from continued treatment.
Patient is currently enrolled in a Novartis-sponsored, CD&MA study receiving everolimus or everolimus plus Sandostatin LAR Depot and has fulfilled all their requirements in the parent study
Patient currently requires systemic therapy.
Patient is currently receiving medication(s) that are principally metabolized via the cytochrome P450 3A4 enzyme pathway.
Currently tolerating treatment in the parent protocol.
Currently receiving or has received treatment with systemic steroids in the following dosages within 30 days prior to administration of the first study vaccination.
Currently receiving active therapy for other neoplastic disorders
Part 2: currently receiving anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and/or tricyclic drugs (imipramine, clomipramine, or desipramine)
Patients currently being treated with quinacrine or drugs related to quinacrine
Patients currently receiving any medication known to induce central serous chorioretinopathy which in the opinion of the principal investigator, would make the administration of study drug hazardous
Receiving phenytoin
Women who are currently or planning to breastfeed during protocol treatment
Not currently receiving therapy
Patients must not be currently receiving immunosuppressive drugs such as corticosteroids, tacrolimus or cyclosporine
A 7-day washout period is required if patients are currently using another oral topical treatment for mouth lesions; patients currently using clobetasol oral topical treatment are not eligible for this study
Subject is currently using or use within 6 months of illicit drugs.
Currently receiving chemotherapy, radiation therapy, immunotherapy, or biotherapy for breast cancer
Currently receiving nivolumab and considered by Investigator to have the potential to derive clinical benefit from continuing treatment with nivolumab.
Currently receiving therapy with a UDP-glucuronosyltransferase 1A9 inhibitor including diclofenac, imipramine, ketoconazole, mefenamic acid, and probenecid
Currently receiving hormone replacement therapy, unless discontinued prior to screening
Patient is currently enrolled in an eligible Novartis-sponsored study and receiving ribociclib (LEE011) as single agent or in combination with other investigational treatment.
Patients who are currently receiving treatment with agents that are known to cause QTc prolongation in humans (Refer to Appendix 3)
Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior to starting study drug Ribociclib:
Patient is currently receiving any of the following substances and cannot be discontinued 7 days prior to start the treatment:
Patient is currently using other antineoplastic agents
Currently receiving cancer therapy. Hydroxyurea will be allowed.
Currently receiving or less than 28 days since ending systemic anticancer treatment for unresected stage IIIB to IV melanoma
Patients who are currently receiving angiotensin-converting enzymes (ACE) inhibitors are not eligible
May not be currently prescribed ritonavir, cobacistat and/or zidovudine
Patients who are currently receiving treatment with agents that are known to cause QTc prolongation or inducing Torsade de Pointes in humans and are unable to discontinue or switch to an alternate medication
Concomitant medications:\r\n* Growth factors that support platelet or white cell number or function must not have been administered within the 7 days prior to enrollment (14 days if pegfilgrastim)\r\n* Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the 7 days prior to enrollment are not eligible\r\n* Patients who are currently receiving another investigational drug are not eligible\r\n* Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Patients who are currently receiving the enzyme inducing anticonvulsants: phenytoin, phenobarbital, carbamazepine, oxcarbazepine are not eligible; patients who are currently taking rifampin, voriconazole, itraconazole, ketoconazole, aprepitant, or St. Johnâ€™s Wort are not eligible\r\n* Use of warfarin is not allowed while on study; patients already on warfarin should use alternative anticoagulants while on this study; warfarin must not have been administered within 7 days of starting protocol therapy\r\n* Patients receiving medications that prolong the QTc
Patients who have an uncontrolled infection, or who are currently receiving treatment for Clostridium (C) difficile infection
Patient currently receiving lithium, steroid, chemotherapy or radiotherapy treatment
Currently progressing, resistance to or with a suboptimal response to their most recent therapy
Currently receiving treatment in a different clinical study in which investigational procedures are performed or investigational therapies are administered
Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior start if the treatment:
Active second malignancy, i.e., patient known to have potentially fatal cancer present for which she may be (but not necessarily) currently receiving treatment a. Patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy was completed >6 months prior and/or bone marrow transplant (BMT) >2 years prior to first dose of rucaparib
Patients who are currently receiving treatment with medications that meet one of the following criteria and that cannot be discontinued at least one week prior to the start of treatment with LGH447:
Is currently participating in GSK1120212 study and is receiving treatment with GSK1120212.
Is currently receiving clinical benefit as determined by the investigator from previous treatment with GSK1120212 either as monotherapy or as part of a combination treatment regimen.
Is currently participating in a GSK-sponsored study of GSK2118436
Patients who are currently participating or planning to participate in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study or who are receiving other investigational agents.
Patients currently receiving chemotherapy or radiation therapy.
Currently receiving vismodegib, biologics or chemotherapy
Subjects who are currently receiving or have had previous hormonal, chemotherapy, or radiotherapy for prostate cancer
Patients currently entered on Alopexx Oncology Protocol AO-101
patient was currently enrolled in Novartis sponsored study, which had met its endpoint and was receiving single agent oral dovitinib or dovitinib and fulvestrant coadministration
Patients currently receiving active therapy for other neoplastic disorders
PART II: Currently receiving chemotherapy or radiation therapy
Patients who are currently receiving treatment with agents that are known to cause QTc prolongation in humans.
Patients who are currently receiving active therapy for other neoplastic disorders will not be eligible
Patients who are currently receiving lithium chloride (LiCl)
Patients who are currently receiving active therapy for other neoplastic disorders will not be eligible
Subjects must not be currently using other tobacco or nicotine products.
Active diagnosis of psoriasis or currently receiving treatment for psoriasis.
Currently receiving other GCTB specific treatment (eg, radiation, chemotherapy, or embolization)
Currently using an opioid antagonist or partial antagonist.
NOTE: patients currently receiving warfarin must have approval from an oncologist or their designee to participate in this study
Currently receiving (or scheduled to receive) radiation treatment for a cancer listed in the inclusion criteria
Patient's household is currently receiving or applying for Supplemental Nutrition Assistance Program (SNAP) benefits (formerly known as food stamps)
Currently receiving or expected to start cytotoxic chemotherapy or immunotherapy within 1 week of study enrollment and additional dexamethasone cannot be used concurrently as per attending oncologist.
Patients who are currently receiving physical therapy or practicing yoga for any reason
Currently employed in night shift work
Currently receiving palliative or hospice care
Currently receiving reflexology or meditative practices
Subject must currently be receiving enzalutamide for prostate cancer in a study sponsored by Astellas or Medivation and, based on the investigator's assessment, benefit from continued treatment. Subjects participating in investigator-initiated trials are not eligible.
Subject is currently participating in an investigator-initiated interventional trial and receiving enzalutamide.
Patients currently receiving anti-convulsants (such as gabapentinoids, e.g. gabapentin (Neurontin) or pregabalin (Lyrica) will be tapered off these medications over 7 days; the study team will provide instructions on how to do this
Currently receiving acupuncture for any condition or if they have ever used acupuncture before
As per self-report, currently engaged in ongoing psychotherapy
Currently on gabapentin
Currently residing in nursing or assisted living facility
Currently practicing nurse
Subjects currently participating in a RT program
Currently on gabapentin or pregabalin; note: (all patients on these medications will be weaned off of them prior to study initiation; the study team will provide instructions on how to do this)
Patient is currently on antibiotics
Currently receiving rehabilitation
At the time of recruitment the patient is on active treatment defined as either currently receiving chemotherapy or radiation or less than 6 months post-cancer surgery
Currently walking =< 30 minutes/day for < 5 days a week (via self-report)
Currently walking, on average, more than 150 minutes per week
Currently receiving or have plans for adjuvant radiation or chemotherapy
Currently receiving gabapentin or pregabalin and not willing to be weaned off of these medications prior to Scrambler therapy initiation\r\n* Note: it is OK to continue these medications in patients who are receiving TENS
Currently receiving anti-convulsants (such as gabapentinoids, e.g. gabapentin [Neurontin] or pregabalin [Lyrica]); all patients on these medications will be weaned off them prior to study initiation
Currently receiving other alternative treatment for CDI (e.g. antibiotics other than metronidazole or vancomycin; probiotics; immunoglobulin therapy; fecal transplant)
Patients currently using a wearable activity tracker
Currently participating in couple/marital therapy
PATIENT: Currently receiving hospice care
INTERVENTION PHASE: Currently receiving acupuncture treatment for CIPN
Patients who are currently receiving acupuncture for any condition or if they have ever had acupuncture before
CANCER PATIENT GROUP: Currently receiving ADT treatment for at least 6 months (and continue to receive treatment during the duration of the study)
Currently receiving other intravesical chemotherapy.
Currently receiving Dilantin (phenytoin) or auranofin or another gold-containing compound
Currently receiving immune-modulating therapies
Patients currently receiving therapy for mucositis
Participant is currently receiving treatment with fluvoxamine
Participant is currently receiving treatment with immunosuppressants or corticosteroids
Participant is currently receiving treatment with nifedipine (Procardia XL)
Currently receiving anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, clonidine, and/or tricyclic drugs (imipramine, clomipramine, or desipramine)
Be currently receiving anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and/or tricyclic drugs (imipramine, clomipramine, or desipramine)
Patients who are currently receiving acupuncture for any condition or if they have ever had acupuncture before
Currently receiving chemotherapy or radiation
Subjects may be currently prescribed hormone treatment or Herceptin therapy
Patients currently participating in a meditation practice for more than 1 hour per week prior to preoperative visit
Currently receiving chemotherapy
Currently prescribed plavix (clopidogrel)
Currently weighs > 350 pounds
Currently receiving anticoagulant therapy
Currently receiving therapeutic anticoagulant therapy or dual antiplatelet therapy (e.g. aspirin and clopidogrel)
Currently on the wait list for a new garden
Currently participating in a smokeless tobacco cessation study
Participants must not be currently receiving or have previously received thiazolidinedione treatment unless sputum atypia or endobronchial dysplasia are documented again after thiazolidinedione treatment and within 12 months of entry
PILOTS II and III: Currently receiving radiation therapy or cytotoxic chemotherapy
For nicotine replacement therapy (NRT) (patch, gum, lozenge):\r\n* History of severe eczema or any serious skin problem if requested nicotine patch\r\n* History of severe allergic reaction to the nicotine patch or other skin adhesives\r\n* History of heart attack in the last 2 months\r\n* Currently experiencing frequent angina or chest pain related to heart\r\n* Currently experiencing signs and symptoms of peptic ulcer\r\n* Currently receiving medications for rapid or irregular heart beat\r\n* Currently experiencing signs and symptoms of severe, uncontrolled high blood pressure
Presence of at least 1 CV risk factor:\r\n* Currently on medication for hypertension, or\r\n* Currently on medication for cholesterol or triglyceride, or\r\n* Currently on medication for diabetes, or\r\n* Currently not physically active (self-reported average < 20 minutes/day), or\r\n* Currently smoking.
Currently institutionalized
Currently on the wait list for a new garden
Not currently using immunosuppressant medications
Pregnancy in the last 6 months/planned within the next 2 years or currently lactating
Currently receiving vismodegib, biologics or chemotherapy
Currently receiving or planning to receive other xerostomia treatment, including drugs, herbs or devices; all other treatments known to affect salivation should be stopped at least 14 days prior to enrollment
Currently receiving treatment for any malignancy
Patients who currently have stomatitis/oral mucositis/mouth ulcers;
Currently receiving immunosuppressive therapy to include chemotherapy, steroids, or methotrexate
Subject is currently receiving anticoagulation therapy other than acetylsalicylic acid
currently minimally active,
Not currently receiving cancer-directed therapy
Currently receiving immunotherapy
Not currently on ADT
Is currently receiving and able to discontinue erlotinib, gefinitib, afatinib, or osimertinib
Currently treated for hyperthyroidism
Presence of synchronous malignancy for which the patient is currently receiving active treatment
Not currently receiving radiation treatment for a cancer listed in the arm-specific inclusion criteria (Arms 2 and 3)
Currently receiving treatment for a cancer other than those listed in the arm-specific inclusion criteria (exception: the study does not exclude those receiving treatment for non-melanoma skin cancer) (Arms 2 and 3)
Patients currently receiving active therapy for any cancer, including CRC or NSCLC
Currently fasts 12 hours or more (on either of two 24 hour diet recalls, conducted during interim 1)
Criteria 4, Participant is currently receiving or has received liver metastatic-directed therapy ( eg: radiation, ablation, embolization) less than 4 wks prior to enrollment or hepatic surgery
Patient currently receiving or had prior treatment for the currently diagnosed breast cancer.
Are currently receiving other medications or radiation intended for the treatment of their malignancy
